Clinical Trial Update: A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate [Phase 1]

View source ↗

Summary

Phase 1 study reporting blood concentrations of paliperidone after administration of paliperidone palmitate in schizophrenia patients; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED